^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GT201

i
Other names: GT201, Autologous tumor infiltrating lymphocyte injection, GT 201
Associations
Trials
Company:
Grit Biotechnology
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
4ms
New trial • Metastases
|
GT201
4ms
Enrollment open • Combination therapy • Metastases
|
GT201
8ms
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P=N/A, N=32, Not yet recruiting, Grit Biotechnology | Trial completion date: Jan 2027 --> Apr 2027 | Initiation date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jan 2027 --> Apr 2027
Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
|
GT201
9ms
Enrollment open • Combination therapy
|
GT201
10ms
Enrollment change • Combination therapy • Metastases
|
GT201
11ms
New trial • Metastases
|
GT201
11ms
New trial • Combination therapy • Metastases
|
GT201
almost1year
New P1/2 trial • Metastases
|
GT201
1year
Phase classification • Metastases
|
GT201
over1year
A Functionally Enhanced Tumor-Infiltrating Lymphocytes Product (GT201) Exhibits Improved Persistence and Anti-Tumor Efficacy with Low IL-2 Dependency (ASGCT 2023)
Taken together, GT201 demonstrated enhanced persistence and anti-tumor efficacy with low IL-2 dependency in vitro and in vivo. Currently, manufacturing process of GT201 TIL product has been successfully developed (StaViral®), and clinical assessment of GT201 as a next-generation TIL therapy is ongoing in an investigator-initiated trial in China.
Clinical • Tumor-infiltrating lymphocyte
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2)
|
IL2-L
|
GT201